by BioKier | Apr 30, 2022 | Recent News
Despite significant delays related to COVID-19, in late 2020 BioKier completed a 4-week study of BKR-017 (orally administered colon-targeted, sustained-release 500 mg butyrate tablets) in type 2 diabetes (T2D) subjects. Dr. Kishore Gadde’s team at Pennington...
by BioKier | Jan 26, 2021 | Recent News
Despite significant delays related to COVID-19, in late 2020 BioKier completed a 4-week study of BKR-017 in type 2 diabetes subjects. Dr. Kishore Gadde’s team at Pennington Biomedical Research Center (PBRC) successfully recruited and enrolled 14 subjects in the study....
by BioKier | Oct 1, 2019 | Recent News
Mayo Clinic in Rochester MN working together with BioKier, Inc. have been awarded a $386,760 SRA Grant by JDRF (formerly known as the Juvenile Diabetes Research Foundation) to Conduct a study in Type 1 Diabetes Patients. Adrian Vella MD (Mayo clinic, Rochester, MN)...
by BioKier | Oct 1, 2019 | Recent News
BioKier has been awarded a $3.0 million Phase IIb Small Business Innovation Research (SBIR) Grant by The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), an institute of The National Institutes of Health (NIH). The grant will fund $1 million...
by BioKier | Oct 1, 2019 | Recent News
BioKier completed a four-week clinical study with BKR-013 (L-glutamine in colon-targeted, sustained-release capsules) in Type 2 diabetes patients, who were already being treated with approved anti-diabetes drugs. This study was supported by an NIH SBIR grant. Fourteen...
by BioKier | Jan 1, 2018 | Recent News
BioKier initiated a clinical trial of BKR-013 colon-targeted capsules in collaboration with Pennington Biomedical Research Center, Baton Rouge, LA. This study will examine the Effect of BKR-013 on Average Daily Glucose Levels. This trial is registered on...
